Safety and Efficacy of Seladelpar in Primary Biliary Cholangitis Patients with Cirrhosis

被引：0

作者：

Bowlus, Christopher L. ^{[1
]}

Hirschfield, Gideon ^{[2
]}

Bacon, Bruce R. ^{[3
]}

Galambos, Michael R. ^{[4
]}

Harrison, Stephen A. ^{[5
]}

Odin, Joseph ^{[6
]}

Amato, Gianni ^{[7
]}

Steinberg, Alexandra ^{[8
]}

Rosenbusch, Scott ^{[9
]}

Bergheanu, Sandrin ^{[10
]}

Boudes, Pol ^{[8
]}

机构：

[1] UC Davis Sch Med, Div Gastroenterol & Hepatol, Sacramento, CA USA

[2] Univ Birmingham, Natl Inst Hlth Res, Birmingham Biomed Res Ctr BRC, Birmingham, W Midlands, England

[3] St Louis Univ, Div GI & Hepatol, St Louis, MO 63103 USA

[4] Digest Hlth Care Atlanta, Atlanta, GA USA

[5] Pinnacle Clin Res Ctr, San Antonio, TX USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] 7999 Gateway Blvd, Newark, CA USA

[8] CymaBay Therapeut, Clin, Newark, CA USA

[9] Cymabay Therapeut, Newark, CA USA

[10] Saberg Clin Res, The Hague, Netherlands

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1898

引用

页码：1077A / 1078A

页数：2

共 50 条

[1] PHARMACOKINETICS OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS, WITH OR WITHOUT CIRRHOSIS
Mao, Lily
Bowlus, Christopher L.
Levy, Cynthia
Odin, Joseph
Stanca, Carmen M.
Trivedi, Palak
Varga, Monika
Bergheanu, Sandrin
Yang, Ke
Steinberg, Alexandra
Rossi, Stephen
Boudes, Pol
[J]. HEPATOLOGY, 2019, 70 : 807A - 808A
[2] Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, Allyce
Trudeau, Sheri
Gordon, Stuart C.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (11) : 1517 - 1523
[3] EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH COMPENSATED CIRRHOSIS AND EVIDENCE OF PORTAL HYPERTENSION DUE TO PRIMARY BILIARY CHOLANGITIS (PBC)
Levy, Cynthia
Odin, Joseph
Neff, Guy W.
Trivedi, Palak
Gheorghe, Liliana-Simona
Bowlus, Christopher L.
Vierling, John M.
Gulamhusein, Aliya F.
Jeong, Sook-Hyang
Xu, Emily
Yang, Ke
Choi, Yun-Jung
Watkins, Elaine
McWherter, Charles
[J]. HEPATOLOGY, 2021, 74 : 762A - 763A
[4] Seladelpar for primary biliary cholangitis
Baker, Holly
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (06): : 510 - 510
[5] Seladelpar for primary biliary cholangitis
Baker, Holly
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (05): : 414 - 414
[6] Seladelpar in primary biliary cholangitis
Kotsiliti, Eleni
[J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (05) : 300 - 300
[7] Seladelpar in primary biliary cholangitis
Eleni Kotsiliti
[J]. Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 300 - 300
[8] Seladelpar: New hope for patients with primary biliary cholangitis
Nevzorova, Yulia A.
Cubero, Francisco Javier
[J]. MED, 2024, 5 (05): : 377 - 379
[9] Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
Mishra, Ajay Kumar
Singh, Satender Pal
[J]. JOURNAL OF HEPATOLOGY, 2022, 77 (05) : 1474 - 1474
[10] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies
Gordon, Stuart C.
Trivedi, Palak
Bowlus, Christopher
Michael, Galambos
Goel, Aparna
Gulamhusein, Aliya
Levy, Cynthia
Neff, Guy
Stanca, Carmen
Thorburn, Douglas
Bacon, Bruce
Borg, Brian
Doerffel, Yvonne
Forman, Lisa
Freilich, Bradley
Gheorghe, Liana
Gonzalez, Maria Sarai
Harrison, Stephen
Huang, Jonathan
Jeong, Sook-Hyang
Kim, Seung Up
Lake, John
Odin, Joseph
Tak, Won Young
Tobias, Hillel
Vierling, John M.
Yang, Ke
Steinberg, Alexandra
Choi, Yun-Jung
McWherter, Charles
Mayo, Marlyn J.
[J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S686 - S687

← 1 2 3 4 5 →